Terug naar overzicht

Three South African companies open offices in The Hague region

From left to right: Wayne Abegglen (Regional Property Executive Hyprop Investments Ltd.), Guido Landheer (Director of Economic Diplomacy and Transition), Karsten Klein
(Deputy Mayor The Hague), Maruis Conradie (Strategy Director NuvaLaw), Jeroen Nijland (Commissioner NFIA).

“We are looking forward to Hystead, IoT.nxt, and NuvaLaw joining professional and creative forces with other Dutch and international businesses in The Hague, and nearby cities such as Leiden.” They are a great addition to our innovative and fast-growing ecosystem in this region”, commented The Hague’s Deputy Mayor Karsten Klein. Expanding to The Hague region The three diverse companies are a boost for the region, and are deemed to have a beneficial impact on the Dutch economy. Hystead Limited is a leading specialist shopping centre fund that operates a portfolio of shopping centres in South-Eastern Europe. They are planning on opening one of their management offices in The Hague. IoT.nxt is a provider of a globally leading IoT platform that enables companies to integrate and leverage all of their existing investments and systems – the enabler of rapid digitization and embracing of the 4th industrial revolution.

NuvaLaw is a LegalTech company that designs and implements digital platforms that transform the way the legal information exchange is managed and how disputes are settled. It is currently focused on reducing inter-party costs between insurers. The company is an alumnus of the Startupbootcamp in London and is also engaging with The Hague Institute for Innovation in Law. NuvaLaw will set up in Leiden to initially partner with large insurance companies in The Netherlands, especially in The Hague and Leiden.

“We are very excited to establish one of our management offices in The Hague to look after our growing SEE shopping centre portfolio,” said Yvette van der Merwe, COO Hystead. “Our office in The Hague will function as the base for international expansion. We are specifically building partnership with world leading system integrators in the field of IoT. These partnerships will allow us to scale up even faster and enable more businesses to access the benefits of our IoT solution,” commented the company’s CMO Joe Bester.

“We like the open innovation that takes place in the Netherlands. The Hague region is especially attractive as it hosts many of the big insurance companies with whom we hope to partner. Collaboration and Access to Justice are part of our company DNA and so this region is a natural cultural fit for us as we expand into Europe,” explained Maruis Conradie, Strategy Director at NuvaLaw.

Volvo Ocean Race 2017

Dutch Economic Mission

The City of The Hague is in collaboration with The Netherlands Enterprise Agency in Cape Town for a Dutch Economic Trade Mission focusing on water and technology-oriented products, services and solutions, or companies that can contribute to a future-proof society. Over 20 companies travelled together with the City of The Hague and The Hague Business Agency to Cape Town. The Mission comes together with one of the official stops of the Volvo Ocean Race. The Hague will be the final destination for the finish of the Volvo Ocean Race in 2018.

“During the economic mission we look at the international opportunities in Cape Town and South Africa, but we also want to be an attractive location for South African companies that want to expand to Europe. It’s wonderful to experience the business opportunities the Volvo Ocean Race creates in light of the 2018 finish in The Hague.” Karsten Klein Deputy Mayor The Hague.

Terug naar overzicht
Bootje brengt polder in Delfland in kaart-980x450px

Water quality is no longer tested by hand, but with a remote-controlled boat. Foto and video Hoogheemraadschap Delfland © Hoogheemraadschap Delfland

“A remote controlled boat, with sensors and measuring equipment, is sent off through the ditches in the polder to continuously measure the variations in water quality”, Miriam Klazenga, spokesman of Hoogheemraadschap Delfland explains. “For example, the boat is equipped with an instrument that measures oxygen, acidity, salinity and the temperature in the water”. With this new method, the hoogheemraadschap aims to get a grip on discharges and leakages from the greenhouse horticulture area

The high tech boat was developed by the US company Platypus from Pittsburgh. “And was made there at a local university”, says the spokesman.

Premiere

Delfland is first in the Netherlands to deploy this innovative boat. “It has been deployed regularly in the US, but not yet in the Netherlands.” The project is still in a pilot phase, but will save a lot of work, according to Klazenga. At the moment, the polder is still being mapped by manual measurements. This is very labour inensive and less accurate, since we can only measure on a limited amount of locations per ditch. The Platypus boat checks the entire ditch.

Introduction on the Dutch market

American company Platypus was consulted by VanPaz in entering the Dutch / European market. Being able to successfully deploy pilots in the challenging water sector was essential to the selection of a location for their business. InnovationQuarter is supporting Platypus with presenting their business in the Dutch ecosystem. For example, Platypus presented their products to a large audience at the annual InnovationQuarter event and introduced the American CEO to Waterschap Delfland, which eventually led to this exciting result.

We are looking forward to supporting Platypus in their next steps conquering the Dutch market!

Source / AD.nl

 

Terug naar overzicht

The Netherlands in Top 10 on IMD World Talent Ranking 2017

The Netherlands in Top 10

The prestigious annual IMD World Talent Ranking assesses the methods countries use to attract and retain the talent their businesses need to thrive.

Europe continues to dominate the 2017 list, with 11 out of the 15 most talent competitive economies based on the continent, after a strong performance in 2016. Switzerland, Denmark and Belgium remain the most competitive countries in the 2017 IMD World Talent Ranking. Austria, Finland, Germany, Luxembourg, the Netherlands, Norway and Sweden make up the Top 10.

IMD World Talent Ranking

The annual IMD World Talent Ranking report covered 63 countries and assessed the methods the countries adopted to attract and retain talent. The rankings are based on a country’s performance in three main categories: investment and development, appeal, and readiness. The Netherlands was ranked 3rd, 7th and 15th on these terms, respectively. The three categories assess how countries perform in a wide range of areas. These include education, apprenticeships, workplace training, language skills, cost of living, quality of life, remuneration and tax rates.

It is European countries’ outstanding education systems that set them apart from the rest of the pack. On average, each has a high level of investment in education accompanied by a superior-quality educational system, from primary to tertiary levels. This allows them to develop local talent and at the same time attract foreign, highly-skilled professionals, which many European businesses rely upon to perform.

The Netherlands in Top 10 on IMD World Talent Ranking 2017 (page 73)

The Dutch score

The Netherlands entered the Top 10 and is in 6th place in the IMD World Talent Ranking 2017.

The Netherlands ranked 3rd in the investment and development category, with a strong performance in health infrastructure (2nd) and its effective implementation of apprenticeships and the prioritization of employee training (both 6th).

The country ranks 7th in appeal, mostly because of the well-educated and skilled people (3rd), a  high quality of life (5th) and a high worker motivation (5th). The Netherlands is also ranked first for language skills.

 

Source / IMD

Terug naar overzicht

Medisch Artificial Intelligence bedrijf Quantib uit Rotterdam

Faster and more objective diagnoses by automatic interpretation of MRI and CT scan data

Founded in 2012 and headquartered in Rotterdam, The Netherlands, Quantib is one of the most renowned Dutch players in the field of medical AI applications. Quantib utilizes ML software for the segmentation, classification and quantification of medical images, improving diagnostic quality and allowing for a more efficient workflow of physicians and researchers. Quantib is a spin-off of the Erasmus MC, developing her products in close collaboration with the internationally recognized Biomedical Imaging Group Rotterdam (BIGR) under supervision of Prof. dr. Wiro Niessen.

Moreover, Quantib has strong partnerships with industry players (GE Healthcare, Philips and Intrasense) for research, development and the distribution of her products. Recently, Quantib received media coverage as winner of The Dutch Data Science prize. Quantib’s first products received FDA approval and CE marking in 2016 and focus on the detection and tracking of neurological disorders such as Parkinson, Multiple Sclerosis and Alzheimer’s disease.

The investment allows Quantib to bring new ML applications to the market with regards to stroke, lung disorders, oncology and bone structures. Quantib will also establish new partnerships with leading international academic hospitals.

In conjunction with the investment, the management team has been reinforced with Arthur Post Uiterweer (former Philips and Boston Consulting Group) and Jorrit Glastra (former Shell). The supervisory board will consist of Prof. dr. Gabriel Krestin, Harm-Jan Wessels and health entrepreneur Jaap Maljers.

Investment in Quantib

Rudolf Scholte, CEO of Quantib: “Our software supports radiologists and neurologists with their objective assessment of MRI- and CT scans. Our deep learning algorithms can support better diagnoses, and a better assessment of treatments’ effectiveness. Up until now, our main focus was on brain disorders. This investment allows us to develop new products and to extend our team.”

“Quantib’s applications help standardise and speed up image analysis and allows for the detection of subtle changes over time. It increases the objectivity of the diagnostic process and therefore delivers an improved diagnosis combined with more efficient processes, positively impacting a large group of patients. We see large international growth opportunities for the company and we are proud to be a part of this development.” says Ewout Prins, Managing Partner Holland Venture.

Francis Quint, Head InnovationQuarter Capital: “Quantib facilitates faster, better and more efficient diagnoses, a fantastic result from the close collaboration with Erasmus MC. We are happy to support this Rotterdam-based company with their ambition to extend the range of their current technology to other applications.”

Terug naar overzicht

Magnitude Space wordt Hiber en opent nieuw R&D Centrum Delft

Rebranding: Magnitude Space becomes Hiber

Dutch satellite company Magnitude Space is rebranding under a new name, Hiber, to reflect the importance of the launch of its new Low Power Global Area Network (LPGAN) in 2018. According to Hiber, the LPGAN represents the company’s transition to a “global internet service company” rather than one focused exclusively on space.

Helping tackle climate change, grow crops more efficiently, manage natural resources better, and even protect wild animals are just a few of the company’s goals. Hiber’s LPGAN service delivers affordable access to their global satellite network and allows data to be easily and cheaply transferred via the internet from the remotest locations.

‘To that end, Hiber is no longer a ‘space’ company. We are an ‘Earth’ company. Our mission is to work with and enable business partners and individuals wherever they are on our beautiful planet,” said Hiber Chief Executive Officer (CEO) Ernst Peter Hovinga.

According to Hiber, the new name also highlights the technology at the core of its LGPAN, as the modem “hibernates” until a satellite passes over to downlink data.

Opening Hiber R&D Center – Small Sat Delta

Hiber recently opened a new Research and Development (R&D) center in Delft Working in collaboration with Hyperion and ISISpace, the teams at Delft will develop software and hardware for enhanced connectivity and facilitate the launch of even more satellites, Hiber stated.

 

Source / Hiber / Satellite Today

Terug naar overzicht
EMA vestigt zich in 2019 in Amsterdam-980x450

Bron: Dutch bid for EMA / YouTube.

The EMA relocation is a direct consequence of the United Kingdom’s decision to leave the European Union. EMA has been based in London, UK, since it was established in 1995 and currently employs around 900 staff members at its headquarters in Canary Wharf, London. A total of nineteen cities from across the EU made bids to host the agency, with Amsterdam coming out on top. EMA Executive Director Guido Rasi stated, “My staff and I are very honored that so many Member States showed an interest in hosting EMA.”

Dutch Minister of Foreign Affairs Halbe Zijlstra was very positive about the result: ‘This is a fantastic outcome. It’s good for the Netherlands, but above all, it’s good for EU citizens who can continue to count on high-quality medicines and proper supervision of medicines. It shows that we can tackle the effects of Brexit with resolve.”

Professor Rasi was happy with the Amsterdam decision: “Amsterdam ticks many of our boxes. It offers excellent connectivity and a building that can be shaped according to our needs. I am very grateful that the Member States took into account our requirements for business continuity and gave priority to the protection of public and animal health.”

Efficacy, quality and safety

EMA is the body responsible for assessing the efficacy, quality, and safety of new medicines, for human and animal health, before they are approved for the European market. In addition, the organization supervises the safety of authorized medicines and promotes research into and the development of new medicines. Every year EMA organizes hundreds of meetings for thousands of experts from Europe and further afield.

The organization has approximately 900 highly qualified staff from all the EU member states. A large majority of EMA staff expressed their willingness to move with the agency to the new home in Amsterdam. The EU had set out six criteria to be met when evaluating candidate locations, including the city’s ability to get the agency fully operational on time, transport accessibility, available schooling, and employment opportunities for spouses.

European pharmaceutical network

The Dutch Medicines Evaluation Board (CBG) is a major contributor of expertise to the European network of pharmaceutical authorities coordinated by EMA. A large number of pharmaceutical organizations are currently located in London, many of whom work intensively with EMA. It is likely that at least some of these organizations will want to relocate to the same place as EMA. This could potentially strengthen the Dutch position in European pharmaceutical policy and boost the Netherlands’ attractiveness to companies and institutions in the top sectors of life sciences and health, and agrifood.

Dutch Minister for Healthcare, Bruno Bruins commented: ‘This is good news for all patients across Europe. In Amsterdam, the EMA will be able to continue its important work without interruption after Brexit. The Agency can continue to grant access to new, innovative medicines without delay.” He added: “Now, the real work begins. Amsterdam and the Netherlands as a whole are fully committed to ensuring the EMA’s relocation runs smoothly. We are ready to get started and we will make sure that the EMA’s important work is not disrupted.”

Effective collaboration between EMA and the Netherlands on the basis of the commitments made in its offer to host EMA is the key to ensuring a successful move and the continuation of EMA’s operations with minimal disruption. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.

Source / Investinholland.com

Terug naar overzicht

MOU Greentownlabs-InnovationQuarter-980x450px

The common goal of Greentown Labs and InnovationQuarter is to set up a reciprocal program that enables entrepreneurs and innovators in the cleantech space to gain acces to the Boston and Dutch markets. This soft landing program will assist growth-stage cleantech ventures with market expansion through partnerships and funding opportunities in Boston and the Netherlands.

Emily Reichert, CEO, Greentown Labs: “Last year I had the opportunity to visit The Netherlands and I was so impressed by the quality of the buzzing cleantech ecosystem in the Rotterdam and Delft areas with initiatives like PortXL, Yes!Delft, RDM and CIC leading the charge. I was encouraged by how similar our ecosystems are and the commitment all of our startups have made to solving big energy and environmental challenges.”

We know that by building a bridge between our two communities we will help facilitate global expansion and new market entry for entrepreneurs in both countries. – Emily Reichert, CEO, Greentown Labs

Greentown Labs and InnovationQuarter set up international collaboration for cleantech startups

Rinke Zonneveld: “I am extremily excited about this cooperation with the largest cleantech incubator in the US. I am convinced that Greentown Labs will be the perfect stepping stone for our cleantech companies which are ready to conquer the American market. Of course we are equally thrilled to welcome many Boston based cleantech ventures to our region.”

 

 

Terug naar overzicht
Ncardia-versnelt-internationale-groei-dankzij-105-mln-groeikapitaal

From left to right: Secretary of the state Mona Keijzer of Economic affairs and Climate; Stefan Braam, CEO Ncardia; Gerty Holla, Senior Investment Manager InnovationQuarter; Rinke Zonneveld, Director InnovationQuarter © Verkijk

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural drug discovery and safety solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million Series B financing round. The round was led by Épimède, a Belgium venture capital firm.

The company is is of great social importance as well, with technology that improves the care for heartpatients, reduces the costs of healthcare ans can replace animal testing. -Francis Quint, Head of InnovationQuarter Capital

Ncardia is a privately held company with operations in Europe and the US, that produces and commercializes high-quality, fully functional human iPSC derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes electrophysiology-, biochemistry- and contraction-based assay services for predictive safety pharmacology, toxicology testing and drug efficacy screenings. In addition the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Ncardia believes that stem cell technology fast-tracks the delivery of better medicines to patients by improving the drug discovery process.

Ncardia-versnelt-internationale-groei-dankzij-105-mln-groeikapitaal

F.l.t.r: Leendert Jan Visser, Director MKB Nederland; Secretary of the state Mona Keijzer of Economic affairs and Climate © Verkijk

Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress has been made on product and service programs for drug safety and efficacy screening. We have built strong and dedicated teams for research & development, manufacturing, drug discovery services, and sales & marketing, to execute our plan to become the trusted leader in human iPSC-based drug discovery solutions. I am delighted with the continued support from our current investors and I am very happy to welcome Épimède as our new investor.”

Marc Foidart, Investment Manager at Épimède said: “Ncardia had a very strong and encouraging start. We are convinced of the added value Ncardia will deliver in the coming years. We are very pleased to join the strong syndicate of existing investors and to support Ncardia growth acceleration.”

Secretary of the state Mona Keijzer is pleased with the new investment that Ncardia receives: “Congratulations Ncardia with your new investors. Ncardia is an inspiring example of how a Leiden based company, established by five young scientists, can impact the pharmaceutical industry. Your stem cell technology enables better drug development, benefitting patients all over the world. ”

Francis Quint, InnovationQuarter: “Ncardia is a good example of how a regional startup with unique technology can develop into a leading scale-up within a few years. The company is is of great social importance as well, with technology that improves the care for heartpatients, reduces the costs of healthcare ans can replace animal testing.”

The participants in this funding round include Épimède, InnovationQuarter, SRIW, SambrInvest, Vesalius Biocapital and SFPI-FPIM. The funds raised will be used by Ncardia to speed-up its already promising international growth, to develop the next generation safety assays and to expand capabilities in the cardiovascular drug discovery and high throughput screening domain.

Ncardia-versnelt-internationale-groei-dankzij-105-mln-groeikapitaal

© Verkijk

Terug naar overzicht
Get in the Ring the Netherlands 2017

© Marco De Swart

Get in the Ring

Get in the Ring the Netherlands is organized by the Erasmus Centre for Entrepreneurship (ECE) and supported by the City of Rotterdam and EY. The event took place for the fifth time in Rotterdam and is part of the Global Entrepreneurship Week, a week in which thousands of events take place worldwide that focus on entrepreneurship.

The startups are looking for customers and strategic partners for the growth of their company. ”There are a lot of opportunities for this during Get in the Ring Netherlands. The 70 multinationals and governmental organizations present are happy to be available as customers, suppliers or partners ” says Martin Luxemburg, director of the ECE. Based on requests from the startups, more than 600 speed dates with the participating organizations took place on Thursday. The effect of these conversations appears to be significant; 65 percent of the speed dates result in a follow-up conversation that in some cases even leads to a collaboration.

“It is still too early to say to which collaborations the conversations of this year will lead, but the City of Rotterdam is a nice example. Based on their participation with Get in the Ring last year the City of Rotterdam has started a project with a startup in solar panels that have been placed at test locations in the city” says Martin Luxemburg.

For the startups the speed dates were not the only activity; they were also challenged to qualify for the evening program to ascend the stage and to pitch their startup for a 700-strong audience (read: possible customers, partners or talent) in the ring. No competition without jury members, this year the Champion jury members were the founder of international software company WeTransfer; Bas Beerens, founder of scale-up YoungCapital; Rogier Thewessen, and entrepreneur Janneke Niessen.

Startups Kozie, LABFRESH en Convious winnen Get in the Ring Nederland

And the winners are…

The startups do not step in the ring alone, but will compete against an opponent in their own weightclass. Dementia technology startup Kozie took the win in the lightweight category against SeraNovo. Kozie develops multi-sensor technology that enhances the perception of people with dementia, so that demented people can recover memories from their childhood through a music pillow or music rug. The middleweight winner is LABFRESH after a strong pitch battle against Somnox. LABFRESH sells clothing of a special material that does not stain and smell. The heavyweight winner Convious offers a platform where people can buy tickets and determine the price themselves. Convious was in the ring against Felyx. The three winning startups receive a ticket to the Global Meetup of Get in the Ring. In addition, they receive 1 year access to the EY Finance Navigator. This Finance Navigator is the first corporate startup of EY and was launched yesterday during the event.

Get in the Ring The Netherlands is part of a worldwide network of the Get in the Ring Foundation, which annually organizes 150 events in 100 countries. The winning startups of all these events worldwide will meet in Cascais, Portugal, from 30 May to 1 June, during the Global Meetup of Get in the Ring. Entrepreneurs, investors and corporates can join the Global Meetup, which is entirely dedicated to establishing international connections.

Terug naar overzicht

The Dutch Life Science sector present at MEDICA 2017

MEDICA 2017

MEDICA exists for more than 40 years and attracts every year ten thousands of visitors. This year over 5,000 exhibitors from over 70 countries were represented. MEDICA presents the entire spectrum of innovations for outpatient and clinical care. The five main themes were:

  • Electromedicine & Medical Technology
  • Information and Communications Technology
  • Physiotherapy & Orthopaedic Equipment
  • Laboratory Equipment & Diagnostics and Disposables
  • Commodities and Consumer Goods

The Dutch Life Science sector present at MEDICA 2017

Holland Pavilion

For the 7th time, the Netherlands was well represented at the Holland Pavilion organized by Task Force Health Care and Health~Holland. The Holland Pavilion (300 m2) provided an excellent opportunity to meet the 29 participating Dutch companies and experts from the Dutch Life Sciences & Health sector.

InnovationQuarter was present at MEDICA 2017 to speak to companies that are considering setting up their operations in the Netherlands, and West Holland in particular. Also existing ties with fellow trade and investment agencies overseas have been strengthened and new contacts were made.

Terug naar overzicht
10 aerospace startups successfully pitched at First Starburst Selection Committee event in the Netherlands

Foto: Remco Zwinkels

Access to International Aerospace Corporates

In an interactive setting in the Auditorium of tech incubator YES!Delft, ten selected startups and scale-ups had the opportunity to present their business to an audience of around a 100 professionals from the industry, amongst them many representatives of larger aviation, aerospace and defence companies and several venture capitalists and business angels.

The 10 pitching companies included:

Aiir Innovations
T4i
Skel-Ex
Selko.io
Fiberneering
Dawn Aerospace
Robin Radar
IMSystems
Decanter
Optics 11

Out of the ten companies, seven were from the Netherlands, giving the corporate partners a good and diverse insight into the possibilities of cooperating with the Dutch aerospace cluster. – Francois Chopard, Founder and CEO, Starburst

“We are glad to present our pitching event in the Netherlands for the first time in our 5 years of existence, following successful events in various metropoles such as Singapore, San Francisco, Montreal and London,” says founder and CEO Francois Chopard “Out of the ten companies, seven were from the Netherlands, giving the corporate partners a good and diverse insight into the possibilities of cooperating with the Dutch aerospace cluster.”

Ten aerospace startups successfully pitched at First Starburst Selection Committee event in The Netherlands-002-980x450px

Foto: Remco Zwinkels

Starburst was invited by the Netherlands Aerospace Group (NAG), InnovationQuarter, the Province of Zuid-Holland and the City of Delft. Deputy mayor Ferrie Förster, congratulated the Paris-based organisation with their first event in the Netherlands and hopes this occasion will be the first of many to come: “We hope Starburst will eventually decide to establish a more permanent base within the Delft  ecosystem”, Förster admitted: “the concept, which provides start-ups with an opportunity to get introduced to large corporates, will inspire a new generation of innovators from this particular cluster.”

Strong international network

The current ecosystem of Starburst counts 2500+ startups globally, covering the widest range of aerospace applications combined with a non-exhaustive list of corporate partners like Thalès, Boeing and Safran. “We’re glad to see these international partners present and actively interacting with representatives from the Dutch ecosystem”, says Frank Jansen, director of NAG. Jansen has been in touch with the organisation for several years and planned the conclusive meeting during the Paris Air Show last June, in which all organizing partners committed to establish the first Starburst Selection Committee event in NL.

The Starburst committee selected 3 international startups, amongst which Decanter from Taiwan, as well as 7 companies from the Netherlands. Deputy Minister for Economic Affairs, Ms. Adri Bom-Lemstra is proud to see that four of the Dutch startups originate in the Province of Zuid-Holland: “Inspiring to see all of these state-of-the-art innovations and concepts from this region”, she says, while trying on SkelEx’s exoskeleton-suit, which makes handling heavy parts or luggage light and easy, “You really notice the excitement of the corporates here on the exhibition floor when they talk to all these smart entrepreneurs from our region; I am convinced this event was also a good ‘pitch’ for our province, demonstrating to the international aerospace cluster that we are a true innovation hotspot!”

 

Terug naar overzicht

Dutch Digital Health Mission to Silicon Valley 2017

CITRIS

For InnovationQuarter, this trade mission builds on the warm relationship with CITRIS that was concluded by the MoU in 2016. CITRIS, the Center for Information Technology Research in the Interest of Society, and the Banatao Institute leverage the research strengths of University of California campuses at Berkeley, Davis, Merced and Santa Cruz, and operate within the greater ecosystem of the University and the innovative and entrepreneurial spirit of Silicon Valley.

Dutch Digital Health Mission to Silicon Valley 2017

Digital Health Mission

The mission was kicked-off by Matthew Holt, well-known of the Health 2.0 conferences, who explained the group the healthcare system in the US and the implications for digital health companies. Several hospital visits ensured the delegation could talk directly to their end-customers and key decisionmakers. The group visited amongst others the San Mateo Medical Center, El Camino Hospital, Stanford and UCSF. Other visits included Kaiser Permanente, Launchpad Digital Health and companies active in the Netherlands such as Medisense.

The mission was closed with the Dutch Digital Health night at the Consulate General of the Netherlands in San Francisco where the companies pitched their product for a crowd of 100 internationals in the digital health sector.

Amongst the participants were the West Holland based New Compliance, Bayards, Topic Healthcare Solutions, Hippus/Handshoemouse and the Rathenau Institute.

Terug naar overzicht

On the way to 3D flexible post processing

Post processing solution

Everyone loves the idea to be able to think up a product, draw it out, push the button and have a beautiful object. Unfortunately, in reality this rarely happens. The object still needs post processing, like removal of struts and polishing. This post processing is the most time consuming process in the chain and therefore a costly step, especially for 3D metal printing.

InnovationQuarter helped set up a consortium for tackling these challenges. After the approval of the EU Interreg 2Seas Programme at the end of 2016, 7 parties teamed up in taking the challenge to research, develop and implement an efficient and fast post processing solution:

  • University of Applied Sciences Rotterdam
  • RDM Makerspace
  • Hittech Multin
  • 3T RPD
  • TNO Innovation for life
  • University of Exeter
  • Argon Measuring Solutions

Challenges of post processing

Each partner having the skill and expertise needed in tackling the 4 main issues that characterize the challenge:

  • flexible clamping of the object during production and post processing;
  • scanning and mapping the object for compliance with the specs;
  • translation to the CAD/CAM interface; and
  • control the polishing the surface of the object.

A prototype of the final setup will be integrated and tested on the demonstrator cases provided by the 24 observer parties supporting the research. The ultimate proof of combining high tech and knowledge into a smart and reliable post production capability.

With its capability to print free forms at high speed, with no waste, on demand and on the spot, we’re moving from mass production to mass customization. This project can bring a revolution in the world of additive manufacturing.

This film gives you an introduction of the project:

Starting up

InnovationQuarter helped set up this project when Senior Business Developer Jacqueline Schardijn picked up the signal that organisations weren’t interested to invest in metal additive manufacturing technique because of the hickups of post processing. By connecting the right partners and creating the right setting of trust and motivation, Jacqueline saw the opportunity to apply this project into the EU Interreg 2Seas Programme. At the end of 2016 the EU approved the project. Jacqueline also linked 4 use case holders to the project to make sure end users are involved who can benefit from the results.

Interested in this project?

Visit the project at their stand at the RapidPro expo on 7 and 8 of March in Veldhoven, where you can hear all about this project.

Terug naar overzicht
InnovationQuarter’s Chris van Voorden overhandigt namens de stad Leiden, NFIA en InnovationQuarter een speciale welkomstplaquette aan Henk Deist, CEO van Atterbury Europe.

Atterbury Europe’s CEO Henk Deist and Chris van Voorden, Director Foreign Investments at InnovationQuarter © Daniel Verkijk

Expanding to Europe

Over 23 years, Atterbury has successfully developed real estate across South Africa and on the African continent. Since 2014 they have expanded their activities into Europe, starting out in Austria and now concentrating operations in Leiden from where the development of prime commercial, retail and residential property in Europe is being effectively managed.

The distinctive ‘Leiden Central Offices’ building is strategically located at the intersection of the historic centre with all its inner-city facilities and Leiden’s central train station. With only a 15-minute train ride, Amsterdam Schiphol Airport is in close proximity, making traveling throughout Europe easy and fast.

Atterbury Europe’s CEO Henk Deist: “As our business grew into a meaningful size, we decided that from an economical and practical perspective our activities should be centrally headquartered in Europe. The Netherlands was chosen, not only for its competitive fiscal regime, but also for its access to top professional advisors and the fact that the Dutch use English as their main business language. We are five employees in the office, that is when we’re not travelling – four South Africans and a Romanian, on the lookout for the first local to join – we have enough space for growth!”

Henk Deist, CEO van Atterbury Europe, en zijn Atterbury-team in Leiden

Henk Deist, CEO Atterbury Europe, and his Atterbury-team in Leiden © Daniel Verkijk

Based in Leiden

Deputy Major Robert Strijk of the City of Leiden: “We’re very pleased that Atterbury Europe is well aware of the attractive Dutch business climate and concluded that Leiden offers great opportunities. The city is an ideal, solid and hopefully prosperous basis from which they can expand their operations in Europe and I have no doubt the Leiden office will soon feel like ‘Die Klubhuis’ for their employees!”

On behalf of the Netherlands Foreign Investment Agency (NFIA) and the City of Leiden, InnovationQuarter’s Director of Foreign Investments Chris van Voorden welcomed Atterbury Europe in Leiden.

Nieuw Europees hoofdkantoor voor Zuid-Afrikaanse vastgoedontwikkelaar Atterbury

Hilde de Boer (City of Leiden), Chris van Voorden (InnovationQuarter), Henk Deist (Atterbury Europe), Annemieke Busch (NFIA) and Arnoud Nierop (City of Leiden) © Daniel Verkijk

Van Voorden says: “The arrival of this highly rewarded South African property developer with an impressive track-record and portfolio, underlines our continuously improving business climate. We have noticed a growing interest from South African companies setting-up business in West Holland. Besides linguistic and cultural similarities, maybe also our direct approach in conducting business is a unique characteristic our countries share. With our partners, we are pleased to help Henk Deist and his team establish useful contacts and support them in their European growth ambitions.”

Terug naar overzicht

UNIIQ_AmylonTherapeutics_Katwijkse-Ziekte-1-980x450px

From left to right: Tim de Jong (UNIIQ), Ivo de Nooijer (LURIS), Tsinat Hailu (Director nonclinical Development Amylon Therapeutics), Robert Strijk, Alderman for Accessibility, Economic Affairs, City Centre and Culture City of Leiden, Liduina Hammer (UNIIQ)

Katwijkse Ziekte and CAA

Amylon Therapeutics develops a therapy against Katwijkse Ziekte, formally called Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch Type (HCHWA-D). Katwijkse Ziekte is a heritable orphan disease which originates from the Dutch city of Katwijk. Currently, there is no therapy for the Katwijkse Ziekte and there is no effective therapy available to prevent the development of the disease. Patients, between 40 and 60 years of age, suffer of severe bleedings in the brain as a result of the development of Amyloïd bèta plaques in the blood vessels walls. Depending on the location and the impact of these bleedings, they can lead to paralysis, dementia, and even death. The progression of the disease is significant: after every event, the risk of new bleeding increases and the condition of the patient worsens with each bleeding. On top of that, the moment of the next bleeding is unpredictable.

I am delighted that with its investment UNIIQ provides Amylon Therapeutics the opportunity to continue the development of a therapy against Katwijkse Ziekte and making the next step towards clinical development – Thomas de Vlaam, founder and CEO Amylon Therapeutics

Katwijkse Ziekte is a special (hereditary) variation of Cerebral Amyloid Angiopathy (CAA), a disease which is known to cause multiple hundreds of thousand of patients worldwide, which are affected by or die from the consequences of CAA every year. Another difference between Katwijkse Ziekte and CAA, apart from the fact that CAA is not hereditary, is that the time of onset of CAA is unpredictable. Besides these differences both diseases are similar. Therefore a development of a successful therapy against Katwijkse Ziekte could be a promising step towards finding a therapy for CAA and potentially Alzheimer’s disease, a disease which is also characterized by the formation of plaques in the brain.

Next step towards clinical development

Thomas de Vlaam: “Due to the hereditary dominant mutation we know for sure that Amyloïd bèta plaques will be formed in the brains of patients. By using our “exon skipping” technology Amylon will be able to stop the formation of the Amyloïd bèta. If we can stop the formation of the plaques we expect to stop the bleedings in the blood vessel walls as well.”. De Vlaam continues: “I am delighted that with its investment UNIIQ provides Amylon Therapeutics the opportunity to continue the development of a therapy against Katwijkse Ziekte and making the next step towards clinical development. Until now there is no cure or therapy for patients with Katwijkse Ziekte, we strive to make a change and help these people.”

“Today we have added another promising Leiden based biotech comapny to our portfolio”, mentioned Liduina Hammer, UNIIQ Fund manager. “By focusing on the development of a therapy for Katwijkse Ziekte Amylon will solve an unmet need: there is no cure or therapy against Katwijkse Ziekte. Using the UNIIQ investment to proof its concept Amylon will be able to make a step towards clinical development”.

Amylon Therapeutics was founded by the ambitious entrepreneur Thomas de Vlaam who is supported by experienced and successful biotechnology entrepreneurs such as founder and former CEO of Crucell, Dinko Valerio. In addition, as ProQR Therapeutics spin-off, Amylon Therapeutics has the profound expertise and experience of its shareholders at its disposal.